# ALNY — Alnylam Pharmaceuticals Inc · catalysts, narrative & risks

**Deep-research report — K3vl4r**  
**Symbols:** ALNY  
**Sources:** 17  
**Published:** 2026-09-18  
**Canonical:** https://app.k3vl4r.com/research/deep-research-alny-alnylam-pharmaceuticals-inc-catalysts-narrative-ris-593

---

## Overview (point-in-time: 2026-11-15)

Alnylam Pharmaceuticals (Nasdaq: ALNY) is a Cambridge, MA–based RNAi therapeutics company with six approved medicines and a broad early-to-late pipeline [[3]](https://investors.alnylam.com/press-release?id=db6ecd67-f517-425f-ab01-177f9e4aab44), [[8]](https://catalystalert.io/company/ALNY), [[15]](https://www.marketscreener.com/news/alnylam-pharmaceuticals-insider-bought-shares-worth-299-526-according-to-a-recent-sec-filing-ce785ed9d98bff20). Over the trailing twelve months the stock has been highly volatile, and the recent driver of attention is the quality of demand for its flagship drug AMVUTTRA (vutrisiran), plus a steady stream of clinical readouts. Below is a synthesis of the last ~1–3 months, cross-checked across sources, with notable inconsistencies flagged.

## Recent catalysts (Aug–Nov 2026)

---

_Preview only. The complete multi-source deep-research report — full thesis, evidence, and citations — is available at https://app.k3vl4r.com/research/deep-research-alny-alnylam-pharmaceuticals-inc-catalysts-narrative-ris-593 (free to sign up)._
